Aerocrine AB

Aerocrine is a medical technology company focused on improving the treatment of patients with inflamed airways. Measuring airways inflammation helps doctors to diagnose, monitor and optimise therapy for people with inflammatory airway diseases.

The founders of Aerocrine emerged from the highly prestigious Karolinska Institute in Sweden where they were the first to identify nitric oxide (NO) as a marker of inflammation. Aerocrine has taken this significant discovery from laboratory to listed company and is now established in some of the world’s largest markets. The company markets two products globally NIOX Flex and NIOX MINO. Both are highly reliable and effective tools to assist in the diagnosis and control of airways disease.

Aerocrine will continue to develop products to improve the quality of life, management and care of people with airways inflammatory disease.

Aerocrine offers versatile, easy-to-use exhaled nitric oxide (NO) monitoring devices for research and clinical applications. All Aerocrine devices use highly accurate methods for measuring minute concentrations of NO, and incorporate NO scrubbers that eliminate atmospheric NO from the patient’s breath. All products comply with international guidelines and are CE-marked for routine clinical use and 510(k) cleared by FDA.

NIOX MINO is a compact hand-held device, ideal for smaller clinics, healthcare centres and hospitals.

NIOX Flex is the successor to NIOX, the first tailor-made device for measuring exhaled nitric oxide (NO). With a new operating system, enhanced data handling facilities and add-on research kits, NIOX Flex is the ideal choice for research applications.